home / press / releases

Menu
  • Search all tables

releases: https://bonamici.house.gov/media/in-the-news/first-round-oregon-v-pharma-state-publishes-data-and-stories-next-trade-secrets

One row per release. Full-text search runs over title + body text.

Data license: MIT · Data source: dwillis/congress-press

This data as json

url title date year month party chamber state member_name bioguide_id domain scraper source date_source text has_text collected_at updated_at
https://bonamici.house.gov/media/in-the-news/first-round-oregon-v-pharma-state-publishes-data-and-stories-next-trade-secrets First Round of Oregon v. Pharma. State Publishes Data and Stories. Next Up: Trade Secrets 2019-12-17 2019 2019-12 Democrat House OR Suzanne Bonamici B001278 bonamici.house.gov     legacy Anger against the pharmaceutical industry is growing. A Gallup poll published in September put the industry at the bottom of the heap among 25 sectors rated annually on their popularity. Nearly 60 percent of respondents said they had a negative view of the industry. People liked government more, with 52 percent seeing bureaucracies in a negative light. Constituent anger has fueled action in Congress. Earlier this year, the U.S. Senate Finance Committee approved the Prescription Drug Price Reduction Act of 2019. That bill, sponsored by Sens. Ron Wyden, D-Ore., and Chuck Grassley, R-Iowa, would cap out-of-pocket drug costs for seniors and penalize drug companies for raising prices faster than inflation, saving taxpayers and seniors more than $110 billion a year. Then last week, the U.S. House passed along party lines the Lower Drug Costs Now Act of 2019, co-sponsored by dozens of Democrats, including Oregon Rep. Suzanne Bonamici. That bill would give the federal government the ability to negotiate drug prices for Medicare and create an international price index. 1 2026-03-30T12:14:52Z 2026-03-30T12:14:52Z
Powered by Datasette · Queries took 0.91ms · Data license: MIT · Data source: dwillis/congress-press